HRMY
Harmony BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The post-earnings bull case is that Harmony preserved its key de-risking signal at T+1: WAKIX still grew 17% year over year, full-year revenue guidance stayed above $1 billion, liquidity remained strong at $870.5 million, and management laid out multiple franchise-extension shots on goal around Pitolisant GR, Pitolisant HD, BP-205, and EPX-100 [#8-K-2026-05-07].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Cost of product sold rose to 20.7% of revenue, driven by new royalties tied to the Novitium license agreement, which can pressure margins even if revenue grows [#8-K-2026-05-07].
Momentum
56
Value
71
Sentiment
40
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $33.00 · Bull $40.00 · Bear $24.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $44.91
Why
Momentum56 · Δ7d -18.4
Value71 · Δ7d +0.2
Sentiment40 · Δ7d +4.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
56
26% active weight
Current posture
7d trendSoftening
Δ7d
-18.4
Δ21d
-33.4
Value
71
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.2
Sentiment
40
34% active weight
Current posture
7d trendImproving
Δ7d
+4.8
Δ21d
+2.7
Why this grade
Composite grade B. Momentum 56.4 / Value 71.1 / Sentiment 40.5
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.94B
Beta
0.84
Shares Out
57.89M
P/E (TTM)
11.6
P/S (TTM)
2.56
P/FCF (TTM)
7.13
Rev YoY
+16.6%
EPS YoY
-29.0%
Gross Margin
+73.9%
Op Margin
+27.3%
Net Debt
-$540.27M
Current Ratio
3.58
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology